Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;50(2):119-123.
doi: 10.1053/j.semnuclmed.2020.02.003. Epub 2020 Feb 21.

Supply and Clinical Application of Actinium-225 and Bismuth-213

Alfred Morgenstern  1 , Christos Apostolidis  2 , Frank Bruchertseifer  2
Affiliations
Review

Supply and Clinical Application of Actinium-225 and Bismuth-213

Alfred Morgenstern et al. Semin Nucl Med. 2020 Mar.

Abstract

The recent development of 225Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated the clinical potential of targeted alpha therapy. Further promising applications of the alpha emitters 225Actinium and its daughter nuclide 213Bismuth include the therapy of brain tumors, bladder cancer, neuroendocrine tumors, and leukemia. This paper will provide a brief overview on the current status of the clinical development of compounds labelled with 225Ac or 213Bi and describe the various production routes that are in place or are under development to meet the increasing demand for these radionuclides.

PubMed Disclaimer

References

    1. Geerlings M.W., Kaspersen F.M., Apostoldis C. The feasibility of Ac-225 as a source of α-particles in radioimmunotherapy. Nucl Med Commun. 1993;14:121–125. - PubMed
    1. Jurcic J.G., Larson S.M., Sgouros G. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233–1239. - PubMed
    1. Rosenblat T.L., McDevitt M.R., Mulford D.A. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res. 2010;16:5303–5311. - PMC - PubMed
    1. Schmidt D., Neumann F., Antke C. Phase I clinical study on alpha-therapy for non hodgkin lymphoma. In: Morgenstern A., editor. Proceedings of the 4th Alpha-immunotherapy symposium; ITU, Düsseldorf, Germany; 2004.
    1. Allen B.J., Raja C., Rizvi S. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther. 2005;4:1318–1324. - PubMed